^
1m
IMPACT OF CO-MUTATIONS ON THE TRANSPLANT OUTCOMES IN AML PATIENTS WITH DNMT3A MUTATION (EBMT 2024)
Notably, none of the patients received oral azacitidine as maintenance therapy... The results indicated that NPM1-/FLT3-ITD- and NPM1+/FLT3-ITD- subgroups in DNMT3A mutated AML benefit from allo-HSCT in CR1. Larger cohorts are warranted to validate these findings.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1)
|
FLT3-ITD mutation • IDH2 mutation • NPM1 mutation • DNMT3A mutation • ASXL1 mutation
|
TruSight Myeloid Sequencing Panel
|
Onureg (azacitidine oral)
1m
IMPACT OF CO-MUTATIONS ON THE TRANSPLANT OUTCOMES IN AML PATIENTS WITH DNMT3A MUTATION (EBMT 2024)
Notably, none of the patients received oral azacitidine as maintenance therapy... The results indicated that NPM1-/FLT3-ITD- and NPM1+/FLT3-ITD- subgroups in DNMT3A mutated AML benefit from allo-HSCT in CR1. Larger cohorts are warranted to validate these findings.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1)
|
FLT3-ITD mutation • IDH2 mutation • NPM1 mutation • DNMT3A mutation • ASXL1 mutation
|
TruSight Myeloid Sequencing Panel
|
Onureg (azacitidine oral)
3ms
Discovery of a germline EZH2 variant reveals Weaver syndrome during sequencing of a B-cell acute lymphoblastic leukemia (B-ALL) (ACMG 2024)
Hematologic malignancies developing in infancy and childhood - including ALL - have been described in two other patients with Weaver syndrome, although heightened cancer surveillance is not currently recommended. Interestingly, one of these patients - who harbored the same EZH2 E745K variant - developed non-Hodgkin lymphoma at 13 years old. This unusual case of ALL arising in both childhood and adulthood supports a potential link between Weaver syndrome and susceptibility to hematologic cancers.
TET2 (Tet Methylcytosine Dioxygenase 2)
|
EZH2 mutation
|
TruSight Myeloid Sequencing Panel
5ms
Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence (ASH 2023)
It effectively allows for bypassing logistical, organizational, and financial burdens, as well as regulatory and ethical concerns. Ultimately, this enables explorative research inquiries into previously inaccessible data sets and offers the prospect of fully synthetic control arms in prospective clinical trials.
Clinical
|
TruSight Myeloid Sequencing Panel
5ms
Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification (ASH 2023)
However, allo-HSCT failed to remedy the dismal outcomes for patients with MDS-biTP53. In conclusion, based on the evidence gathered from this cohort analysis, the 2022 WHO classification promote efficient segregation of this heterogeneous disease, with focus on the differences in molecular features and prognoses across different disease subtypes, leading to accurate MDS diagnosis and effective risk-adapted treatment.
Clinical
|
TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • STAG2 (Stromal Antigen 2)
|
TP53 mutation • TET2 mutation • SF3B1 mutation • STAG2 mutation
|
TruSight Myeloid Sequencing Panel
5ms
Discovery of a germline EZH2 variant reveals Weaver syndrome during sequencing of a B-cell Acute Lymphoblastic Leukemia (B-ALL) (AMP 2023)
Although somatic EZH2 mutations are not well described in B-ALL, germline EZH2 variants have been reported in Weaver syndrome: A rare autosomal dominant overgrowth disorder affecting 50 individuals to date. Close review of her medical record confirmed she had many clinical features of Weaver syndrome: Tall stature (5'11''), a distinctive facial appearance, intellectual disability, a history of developmental delay, and signs of pre- and postnatal overgrowth (99th percentile for childhood growth). Hematologic malignancies developing in infancy and childhood – including ALL – have been described in two patients with Weaver syndrome; however, heightened cancer surveillance is not currently recommended.
TET2 (Tet Methylcytosine Dioxygenase 2)
|
EZH2 mutation
|
TruSight Myeloid Sequencing Panel
5ms
Overcoming Deficient ASXL1 Mutation Detection by Ion Torrent Oncomine Myeloid NGS Assays: Journey of a Molecular Pathology Lab (AMP 2023)
The ASXL1 c.1934dupG variant is now routinely detected in myeloid NGS data using Oncomine Myeloid Assay GX v2 at VAF ³ 10%. Variant calls between 5% and 10% VAF are confirmed by orthogonal testing using the PCR sizing assay. The updated pipeline and sizing assay protocol are available to other laboratories.
Next-generation sequencing
|
ASXL1 (ASXL Transcriptional Regulator 1)
|
ASXL1 mutation • ASXL1 G646Wfs*12
|
Oncomine Myeloid Assay GX • TruSight Myeloid Sequencing Panel
5ms
Case Series of BRAF V600E-mutant Acute Myeloid Leukemia (AML): A Possible Lethal Molecular Sub-group (AMP 2023)
The rapid demise of these two patients with BRAF V600E-mutant AML highlights their poor prognosis. Few cases of BRAF V600E-mutant AML have been described in the literature, all of which reported poor survival. Intriguingly, most cases exhibited monocytic morphology and concurrent KMT2A rearrangements, as was observed in case 2.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
BRAF V600E • BRAF V600 • KMT2A rearrangement • KRAS G12A • KRAS G12 • MLL rearrangement • MLL rearrangement
|
Idylla™ BRAF Mutation Test • TruSight Myeloid Sequencing Panel
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
7ms
A Spectrum of Presentations in Patients With RUNX1 Familial Platelet Disorder With Associated Myeloid Malignancy (CAP 2023)
We identified 3 cases of RUNX1-FPD from our institution with a range of clinical presentations, family histories, and molecular genetic findings. All RUNX1 variants were present with a VAF between 40% and 60%. Age of onset, prior history of bleeding disorder, prior thrombocytopenia, and family history were variable.
Clinical
|
RUNX1 (RUNX Family Transcription Factor 1)
|
TruSight Myeloid Sequencing Panel
9ms
Severe Systemic Auto-Inflammation in an Elderly Woman with Clonal Hematopoiesis (AMP Europe 2023)
The discovery of clonal hematopoiesis in this elderly woman with a wide spectrum of severe auto-inflammatory conditions supports a potentially intriguing link between somatic blood mutations and her adult- onset rheumatologic disorders. Mechanistically, disrupted SRSF2-mediated splicing may be driving aberrant antigen presentation by bone marrow-derived dendritic cells in her skin and other organs. Causal relationships between somatic blood mutations and autoimmune/auto-inflammatory conditions have been established in patients with hematologic malignancies and conditions like VEXAS syndrome.
Clinical
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • SRSF2 (Serine and arginine rich splicing factor 2)
|
IDH2 mutation • SRSF2 mutation • MAP2K1 C121S • IDH2 R140Q • SRSF2 P95L • IDH2 mutation + SRSF2 mutation
|
Oncomine Focus Assay • Oncomine Myeloid Assay GX • TruSight Myeloid Sequencing Panel
9ms
Discovery of a Germline EZH2 Variant, and Underlying Weaver Syndrome, during Sequencing of an Adult B-Cell Acute Lymphoblastic Leukemia (AMP Europe 2023)
Identification of an EZH2 p.E745K mutation about 50% VAF during tumor-only sequencing prompted careful review of the medical literature. Somatic EZH2 mutations are not well described in B-ALL, although germline EZH2 variants have been reported in Weaver syndrome, a rare autosomal dominant overgrowth disorder documented in 50 individuals to date. Close review of her medical record confirmed she had many clinical features of Weaver syndrome: tall stature (5'11''), a distinctive facial appearance, intellectual disability, a history of developmental delay, and signs of pre- and postnatal overgrowth (99th percentile for childhood growth).
Clinical
|
TET2 (Tet Methylcytosine Dioxygenase 2)
|
EZH2 mutation
|
TruSight Myeloid Sequencing Panel
9ms
Validation of a New Next-Generation Sequencing Library Prep Kit for the Detection of Mutations in Hematological Neoplasms (AMP Europe 2023)
The Archer panel presented high performance and good coverage in GC-rich regions as CEBPA gene being a promising test in accuracy of somatic analysis and was validated in our laboratory.
Next-generation sequencing
|
TP53 (Tumor protein P53) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
TP53 amplification
|
Archer® VariantPlex® Myeloid panel • TruSight Myeloid Sequencing Panel
11ms
TARGETED SEQUENCING LANDSCAPE OF A CHINESE PURE RED CELL ANEMIA COHORT (EHA 2023)
We found that rare variants or mutations in myeloid neoplasm-associated genes were detected in PRCA. In our cohort, TET2, ASXL1, GATA2 were frequent in both primary and T-LGLL associated PRCA. Somatic mutation, Pure red cell aplasia, T cell leukemia
DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SETBP1 (SET Binding Protein 1) • GATA2 (GATA Binding Protein 2) • SH2B3 (SH2B Adaptor Protein 3)
|
TET2 mutation
|
TruSight Myeloid Sequencing Panel
11ms
MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY. (EHA 2023)
Our data show that the overall incidence of mutations increases by age up to 65 years, but thereafter remains stable, whereas certain genes have different age distributions. The strong impact of specific genetic alterations on survival in a large population-based study with real-life age distribution is shown. The clinical impact of combinations of specific mutations and karyotypes is being evaluated.
Clinical
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2)
|
TP53 mutation • FLT3 mutation • NPM1 mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation • SRSF2 mutation • STAG2 mutation
|
TruSight Myeloid Sequencing Panel
11ms
TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA (EHA 2023)
We observe that the compound genotype of ASXL1 mutation accompanied by a high mutant TET2 allele burden identified a distinct CMML population with significantly reduced survival, with independent prognostic relevance extrapolated to and validated in an independent cohort. Prospective and large-scale studies are warranted to support these observations and experimental studies are needed to ascertain the underlying mechanistic basis. Figure 1 TET2, Chronic myelomonocytic leukemia, ASXL1, Prognosis
NRAS (Neuroblastoma RAS viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • SETBP1 (SET Binding Protein 1)
|
NRAS mutation • ASXL1 mutation • TET2 mutation • SRSF2 mutation
|
TruSight Myeloid Sequencing Panel
11ms
VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION (EHA 2023)
IPSS-M improved prognostic discrimination and optimized treatments for patients with 2022 ICC-defined MDS. Patients with high, or very high-risk IPSS-M might benefit from HSCT. In addition to 2022 ICC and other parameters, IPSS-M also provided independent prognostication.
Clinical
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • ETNK1 (Ethanolamine Kinase 1)
|
TP53 mutation • FLT3 mutation • DNMT3A mutation • NF1 mutation • SRSF2 mutation • U2AF1 mutation • BCOR mutation • STAG2 mutation • MLL mutation • PPM1D mutation
|
TruSight Myeloid Sequencing Panel
1year
Correlation of MYD88 Allele Frequency by Next Generation Sequencing with Clinicopathologic Findings in Lymphoplasmacytic Lymphoma (USCAP 2023)
We are reporting a positive correlation between MYD88 allelic burden and Clonal B-cell fraction in LPL. Quantitative molecular assay for MYD88 might be useful for evaluation of residual disease in LPL.
Clinical • Tumor mutational burden • Next-generation sequencing
|
TMB (Tumor Mutational Burden) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD19 (CD19 Molecule) • B2M (Beta-2-microglobulin) • PAX5 (Paired Box 5) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1)
|
CD19 positive • MYD88 L265P
|
FoundationOne® Heme CDx • TruSight Myeloid Sequencing Panel
over1year
Downregulation of the Mutated WT1 Alleles in Malignant Hematopoietic Cells Via Nonsense-Mediated mRNA Decay Contradicts Their Prognostic Impact (ASH 2022)
mRNA expression analysis demonstrated that these mutations are strongly regulated by NMD machinery, leading to (almost) complete downregulation of the mutated WT1 allele. These results strongly question any direct effect of WT1 mutations in the leukemic blasts and therefore cannot explain the role of mutations in WT1 as a prognostic factor in AML.
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • WT1 (WT1 Transcription Factor) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1)
|
TP53 mutation • FLT3-ITD mutation • WT1 mutation
|
TruSight Myeloid Sequencing Panel
over1year
RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group (ASH 2022)
This is the most comprehensive study assessing the impact of RUNX1mut in a large pediatric cohort. Unlike adult AML (Gaidzik et al., 2011 and 2016), our results provide evidence for a different clinicopathologic impact of RUNX1mut in pediatric AML, arguing against its classification as a distinct entity in childhood AML. These results may broaden the perspective on the pathological significance of RUNX1mut for leukemogenesis in pediatric AML.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
KRAS mutation • FLT3-ITD mutation • FLT3 mutation • RUNX1 mutation • WT1 mutation
|
TruSight Myeloid Sequencing Panel
over1year
Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients (ASH 2022)
Conclusion We provide evidences that VAF is critical for risk stratification in MDS patients and should be considered in novel scoring systems. Our data fostered our understanding of the mutation burden of the diseases and provided future patient-tailored therapeutic avenues.
Clinical • Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SETBP1 (SET Binding Protein 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
TP53 mutation • FLT3-ITD mutation • IDH2 mutation • FLT3 mutation • DNMT3A mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CEBPA mutation • BCOR mutation • ZRSR2 mutation
|
TruSight Myeloid Sequencing Panel
over1year
Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors (ASH 2022)
FDA approved IDH2 inhibitor enasidenib in 2017 and IDH1 inhibitor ivosidenib in 2018 for adults with relapsed/refractory (R/R) IDH2 and IDH1MT AML. In May 2022, FDA approved ivosidenib combined with azacitidine for adults aged 75 years or older with newly diagnosed AML who cannot undergo intensive induction chemotherapy...IDHi-induced differentiation syndrome (DS) was reported in 6 patients (32%); 4 (21%) who developed DS received Olutasidenib, and 2 (11%) received Enasidenib...All patients with DS were treated with medication discontinuation and intravenous dexamethasone... Only a minority of patients with IDHMT AML had received IDHi-based therapy, which is attributed to patients diagnosed and treated before the FDA approval. Surprisingly, the median survival for patients who didn't receive IDHi therapy seemed not different, underscoring the other therapies' effects, including the influence of the venetoclax-based regimen. More extensive randomized studies are needed to compare the efficacy of IDHi to other therapies in treating IDHMT AML.
Real-world evidence • Clinical
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH2 mutation
|
TruSight Myeloid Sequencing Panel
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Rezlidhia (olutasidenib) • dexamethasone injection
over1year
Clinical
|
SF3B1 (Splicing Factor 3b Subunit 1)
|
SF3B1 mutation
|
TruSight Myeloid Sequencing Panel
over1year
Validation of a 54-Gene Myeloid NGS Panel Using an Independent Tertiary Analysis Software Program (AMP 2022)
The combination of the Illumina Trusight Myeloid Sequencing Panel and the Qiagen Clinical Insight Interpreter tertiary analysis software is a sensitive and specific approach for the detection and interpretation of clinically important variants in myeloid neoplasms.
Next-generation sequencing
|
FLT3 (Fms-related tyrosine kinase 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CALR (Calreticulin)
|
TruSight Myeloid Sequencing Panel
over1year
Targeted Genetic Profiling of Myeloid Malignancies Using Next-Generation Sequencing: Prevalence and Clinical Impact in a Cohort of Lebanese Patients (AMP 2022)
The implementation of this NGS assay allows for a comprehensive evaluation of the mutational spectrum of myeloid malignancies in Lebanese patients. The detection of these actionable gene mutations contributes to an early diagnosis, appropriate individualized treatment, enhanced prediction of target therapy response, and improved clinical outcome.
Clinical • Next-generation sequencing
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BCOR (BCL6 Corepressor) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • GNAS (GNAS Complex Locus) • CALR (Calreticulin) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2) • BCORL1 (BCL6 Corepressor Like 1)
|
TP53 mutation • TET2 mutation • EZH2 mutation • SRSF2 mutation • ABL1 deletion
|
TruSight Myeloid Sequencing Panel
almost2years
MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (EHA 2022)
Conclusion Patients that achieve CR/CRi until FU90 after DLIs have a significantly better outcome than the remaining patients. However, the MRD status in patients in CR/CRi at FU90 had no prognostic effect in the patient cohort investigated here.
Clinical
|
DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
|
DNMT3A mutation • ASXL1 mutation • TET2 mutation
|
TruSight Myeloid Sequencing Panel
almost2years
A REAL WORLD MULTI CENTRE STUDY OF CPX-351 REVEALS NO DIFFERENCE IN OVERALL SURVIVAL WHEN COMPARED WITH FLAG-IDA AND 3+7 IN HIGH RISK AML. (EHA 2022)
Unsurprisingly, ASCT improved OS across all patients irrespective of induction type. Further study with a prospective randomised control trial is required.
Real-world evidence • Clinical
|
TP53 (Tumor protein P53) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2)
|
TP53 mutation • RUNX1 mutation • ASXL1 mutation • SRSF2 mutation
|
TruSight Myeloid Sequencing Panel
|
Vyxeos (cytarabine/daunorubicin liposomal formulation)